<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="57639">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355691</url>
  </required_header>
  <id_info>
    <org_study_id>14-1920</org_study_id>
    <nct_id>NCT02355691</nct_id>
  </id_info>
  <brief_title>Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty</brief_title>
  <official_title>Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kinetic Concepts, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For the target population of adult patients following primary total hip arthroplasty, the
      randomized clinical trial will be used to evaluate the efficacy of the use of a mobile
      negative pressure wound therapy(NPWT) device compared to a standard absorptive dressing in
      the immediate postoperative period. We will apply two dressing types and evaluate the
      postoperative wounds with a wound scoring system (ASEPSIS) that incorporates multiple
      variables of wound infection risk.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Healing by the ASEPSIS criteria</measure>
    <time_frame>Day 0 to 2 weeks post surgery</time_frame>
    <description>A method of evaluating wounds for infection risk that incorporates multiple wound healing factors such as erythema, drainage, and dehiscence is the ASEPSIS (Additional treatment, presence of Serous discharge, Erythema, Purulent exudate, Separation of the deep tissue, Isolation of bacteria, and duration of inpatient Stay) wound scoring system. Originally developed and validated for cardiac surgery sternal wounds, ASEPSIS evaluates the wound for the severity of multiple factors linked with surgical site infection. This includes dehiscence, exudate/discharge, and erythema. The scoring system also includes secondary procedures that increase patient morbidity such as surgical procedures and the use of antibiotics. The higher the score, the more likely a surgical site infection will be present. This score will give us a more diverse picture of postoperative wound healing and the influence of NPWT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Infection</measure>
    <time_frame>Day 0 to 6 weeks post surgery</time_frame>
    <description>We will continue to monitor the patients for development of an acute postoperative infection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Complications; Arthroplasty, Infection or Inflammation</condition>
  <condition>Wound Complication</condition>
  <arm_group>
    <arm_group_label>PREVENA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with the PREVENA negative pressure device following total hip arthroplasty. This dressing will be used for a period of seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be treated with the standard absorptive dressing following total hip arthroplasty.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PREVENA</intervention_name>
    <description>The device is a sealed negative pressure wound therapy tool. The details of the device can be found at http://www.kci1.com/KCI1/prevena.</description>
    <arm_group_label>PREVENA Group</arm_group_label>
    <other_name>KCI PREVENA Incision Management system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Adult patients undergoing primary total hip arthroplasty.

        Exclusion Criteria:

          -  age less than 18 y/o

          -  Total hip arthroplasty for fracture

          -  Revision or conversion total hip arthroplasty

          -  inability to personally consent to participation due to cognitive impairment,
             intoxication or sedation

          -  multiple surgical procedures

          -  Patients taking immune modulating medication(prednisone, methotrexate, anakinra,
             etc.)

          -  skin hypersensitivity to acrylic adhesive or silver.

          -  Inability to care for dressing due to physical or mental incapacitation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Del Gaizo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Orthopaedics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kaitlin Healy</last_name>
    <phone>919-966-9166</phone>
    <email>kaitlin_healy@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UNC Orthopaedics</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaitlin Healy</last_name>
      <phone>919-966-9166</phone>
      <email>kaitlin_healy@med.unc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kci1.com/KCI1/prevena</url>
    <description>PREVENA website</description>
  </link>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 25, 2016</lastchanged_date>
  <firstreceived_date>January 30, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
